Summary & Overview
HCPCS J2277: Motixafortide Injection, 0.25 mg
HCPCS Level II code J2277 represents an injectable formulation of motixafortide dosed at 0.25 mg per unit, used to capture the drug product on outpatient claims. Nationally, drug-specific HCPCS codes matter for accurate billing, prior authorization workflows, utilization tracking, and formulary management across payers. This publication examines coverage and billing practices for J2277 across major national payers and Medicare.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how the code is used in claims, typical sites of service for administration, and the implications for plan coverage and pharmacy/medical benefit distinctions. The report highlights common billing considerations such as unit reporting and where the service is typically delivered.
What readers will learn: benchmarks for use and coverage patterns (where available), relevant policy and documentation issues affecting reimbursement and prior authorization, and clinical context for motixafortide administration. Where input data was not provided, the publication indicates that specific entries are not available and focuses on nationally relevant guidance and observed payer approaches to drug-specific HCPCS coding.
Billing Code Overview
HCPCS Level II code J2277 describes an injection of motixafortide, with each unit representing 0.25 mg. This code denotes the drug product and dosage for administration as an injectable therapy.
Service Type: Drug administration (injectable pharmacologic agent)
Typical Site of Service: Outpatient infusion clinic or ambulatory care setting
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing hematopoietic stem cell mobilization prior to autologous stem cell transplantation for multiple myeloma or non‑Hodgkin lymphoma. The patient has been evaluated by a hematologist/oncologist and scheduled for outpatient or short-stay infusion center administration of motixafortide as part of a mobilization regimen, often combined with granulocyte colony‑stimulating factor (G-CSF). Pre-procedure workflow includes verification of diagnosis, informed consent, baseline vitals and labs (CBC, chemistry), review of prior therapies and potential contraindications, and vascular access assessment (peripheral IV or central venous catheter). The injection J2277 (motixafortide, 0.25 mg unit) is supplied and prepared by pharmacy under sterile conditions; dosing uses multiple billing units based on total milligram dose required. During administration, nursing monitors vital signs and for infusion reactions; observe for local injection site reaction. After injection, the patient may return for additional injections on scheduled days, then proceed to peripheral blood CD34+ stem cell count monitoring and apheresis when mobilization is adequate. Documentation includes indication, lot number and units administered, site of administration, any immediate adverse events, and coordination with apheresis scheduling.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard claim submission |